Brief: HBM Holdings Says Harbour Biomed Receives Chinese Regulatory Approval To Begin Phase II Clinical Trial Of Hbm9161
31/08/2021 11:13
Aug 31 (Reuters) - Hbm Holdings Ltd 2142.HK :
* HBM HOLDINGS - HARBOUR BIOMED RECEIVES CHINESE REGULATORY
APPROVAL OF IND APPLICATION TO BEGIN PHASE II CLINICAL TRIAL OF
HBM9161
Source text for Eikon: ID:nHKS1xFtlD
Further company coverage: 2142.HK
(Reuters.briefs@thomsonreuters.com)
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study